Projects funded by the NCN

Inhibition of p21-Activated Kinase (PAK) as a new molecular target in the treatment of chronic myeloid leukemia (CML)

Call: OPUS 6 , Panel: NZ7

Principal investigator: dr hab. Sylwia Flis

Narodowy Instytut Leków

Mechanism regulating vitamin D analog cooperation with cytostatics and tyrosine kinase inhibitors in non-small cell lung...

Call: PRELUDIUM 5 , Panel: NZ4

Principal investigator: dr Ewa Agnieszka Maj

Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk

Analysis of pharmacokinetic, pharmacodynamic and molecular determinants of intolerance and resistance to the Janus kinas...

Call: OPUS 27 , Panel: NZ7

Principal investigator: dr hab. Marta Katarzyna Karaźniewicz-Łada

Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

Novel aspects of the mechanisms of vascular toxicity of tyrosine kinase inhibitors: studies on their proinflammatory act...

Call: OPUS 26 , Panel: NZ5

Principal investigator: dr Tomasz Krzysztof Prajsnar

Uniwersytet Jagielloński, Wydział Biologii

Investigating the mechanisms of CD20 downregulation triggered by tyrosine kinase inhibitors in Philadelphia chromosome-p...

Call: PRELUDIUM 22 , Panel: NZ5

Principal investigator: Krzysztof Domka

Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego Polskiej Akademii Nauk

Effects of tyrosine kinase inhibitors on Syk pathway in eNOS-based platelet subpopulations and on endothelial barrier in...

Call: POLONEZ BIS 3 , Panel: NZ7

Principal investigator: dr hab. Aneta Iwona Radziwon-Balicka

Uniwersytet Jagielloński, Jagiellońskie Centrum Rozwoju Leków (JCET)

New strategies in the treatment of non-small cell lung cancer based on silk nanocarriers targeting tumor vascularization

Call: SONATA 17 , Panel: NZ7

Principal investigator: dr Anna Katarzyna Florczak-Substyk

Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

RE-SENSE: Dual-loaded lipid nanoparticles to overcome the resistance of non-small cell lung cancer cells to personalized...

Call: PRELUDIUM 20 , Panel: NZ7

Principal investigator: Mikołaj Czajkowski

Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

Iron chelators as tyrosine kinase inhibitors - a new strategy for the treatment of glioblastoma multiforme

Call: PRELUDIUM BIS 2 , Panel: NZ5

Principal investigator: dr hab. Anna Dominika Mrozek-Wilczkiewicz

Uniwersytet Śląski w Katowicach, Wydział Nauk Ścisłych i Technicznych

A novel approach based on the optimized multidrug combination for glioblastoma treatment.

Call: SONATA 16 , Panel: NZ7

Principal investigator: prof. Małgorzata Kucińska

Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

Comparative evaluation of effects of tyrosine kinase inhibitors (TKIs) on endothelial function in vivo in mice

Call: PRELUDIUM 17 , Panel: NZ5

Principal investigator: Brygida Elżbieta Marczyk

Uniwersytet Jagielloński, Jagiellońskie Centrum Rozwoju Leków (JCET)

Insights into biological activity and mechanism of action of novel styrylquinazoline derivatives as tyrosine kinase inhi...

Call: PRELUDIUM 12 , Panel: NZ7

Principal investigator: Katarzyna Anna Malarz

Uniwersytet Śląski w Katowicach, Wydział Matematyki, Fizyki i Chemii

Analysis of the effectiveness of anticancer activity of tyrosine kinase inhibitors combined with nanoparticles in in vit...

Call: SONATA 11 , Panel: ST4

Principal investigator: dr Natalia Piergies

Instytut Fizyki Jądrowej im. Henryka Niewodniczańskiego Polskiej Akademii Nauk

New MOF compounds as degradable nanocontainers of tyrosine kinases inhibitors in novel anti-cancer therapy

Call: OPUS 9 , Panel: ST5

Principal investigator: prof. Artur Piotr Terzyk

Uniwersytet Mikołaja Kopernika w Toruniu, Wydział Chemii

Protein and gene expression analysis in the course of renal cancer stem-like cells' primary resistance to sorafenib in h...

Call: PRELUDIUM 9 , Panel: NZ5

Principal investigator: Zofia Felicja Bielecka

Wojskowy Instytut Medyczny